PDL BioPharma Newswire

PDL BioPharma Newswire

Comprehensive Real-Time News Feed for PDL BioPharma.

Results 1 - 20 of 264 in PDL BioPharma

  1. Pace Holdings Corp (PACE): Hedge Fund Sentiment UnchangedRead the original story w/Photo

    Thursday | Insider Monkey

    ... to other stocks including Vera Bradley, Inc. (NASDAQ: VRA ), Nanometrics Incorporated (NASDAQ: NANO ), and PDL BioPharma Inc. (NASDAQ: PDLI ) to get a better sense of its popularity. We follow over 700 hedge funds and other institutional investors ...

    Comment?

  2. PDL Biopharma's Equity Is A Horse Too Rough To Ride. I Prefer The Fixed IncomeRead the original story w/Photo

    Monday Dec 5 | Seeking Alpha

    In layman's terms, PDL BioPharma, Inc., is a healthcare venture capitalist born in 1983, a time when few knew what venture capitalism was. The company earns money with royalty agreements, patents, license agreements and provides credit financing to a range of healthcare startup or early growth niche operating small companies with favorably high interest rates.

    Comment?

  3. Here's Why PDL BioPharma Inc. Imploded and Fell 32% in NovemberRead the original story w/Photo

    Friday Dec 2 | The Motley Fool

    The sole reason PDL BioPharma fell precipitously throughout the month can be traced to a single event. In mid-November, PDL BioPharma announced that it was planning to issue $150 million worth of senior convertible notes, much of which was going to be used to retire debt that was coming due.

    Comment?

  4. Is PDL BioPharma Inc (PDLI) Going to Burn These Hedge Funds?Read the original story w/Photo

    Friday Dec 2 | Insider Monkey

    ... records, we pay attention to their small cap picks. In this article, we use hedge fund filing data to analyze PDL BioPharma Inc (NASDAQ: PDLI ) . PDL BioPharma Inc (NASDAQ:PDLI) shareholders have witnessed an increase in enthusiasm from smart money ...

    Comment?

  5. RBC says selling in PDL BioPharma overdone; shares still down 15%Read the original story w/Photo

    Wednesday Nov 23 | Seeking Alpha

    The potential haircut to future revenue that PDL BioPharma faces from Eli Lilly's solanezumab flop was already priced into the stock says RBC's Adnan Butt. PDL was eligible to receive royalties on solanezumab sales.

    Comment?

  6. Why PDL BioPharma Inc. Is Down 14.8% TodayRead the original story w/Photo

    Wednesday Nov 23 | Fox News

    In the past, PDL BioPharma made its money from royalty revenue associated with top-selling drugs that relied upon its monoclonal antibody patents. However, these patents expired in 2014, and agreements that allowed the company to collect royalties on some of the world's top-selling medicines expired this year.

    Comment?

  7. PDL BioPharma Issues $150.0 Million of 2.75% Convertible Senior Notes Due 2021Read the original story

    Tuesday Nov 22 | BioSpace

    /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes due aggregate principal amount of 2021 Notes. In addition, PDL has granted the ...

    Comment?

  8. BRIEF-PDL BioPharma issues $150.0 mln of 2.75 pct convertible senior notesRead the original story w/Photo

    Tuesday Nov 22 | Reuters

    * PDL BioPharma issues $150.0 million of 2.75 pct convertible senior notes due 2021 Source text for Eikon: Further company coverage: BRASILIA, Nov 22 Brazilian states will get a share of proceeds from a program to repatriate undeclared foreign funds ...

    Comment?

  9. BRIEF-U.S. CDC says North Miami beach-designated area no longer...Read the original story w/Photo

    Tuesday Nov 22 | Reuters

    * PDL BioPharma issues $150.0 million of 2.75 pct convertible senior notes due 2021 Source text for Eikon: Further company coverage:

    Comment?

  10. PDL Bio closes $150M debt offering; net proceeds almost $146MRead the original story w/Photo

    Tuesday Nov 22 | Seeking Alpha

    PDL BioPharma closes its previously announced offering of $150M aggregate principal amount of 2.75% convertible senior notes due December 1, 2021. Underwriters have the option to purchase an additional $22.5M of the notes.

    Comment?

  11. PDL BioPharma Inc. (PDLI) Shares Sold by Eqis Capital Management Inc.Read the original story w/Photo

    Thursday Nov 17 | Daily Political

    Eqis Capital Management Inc. lowered its position in shares of PDL BioPharma Inc. by 3.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 335,764 shares of the company's stock after selling 12,161 shares during the period.

    Comment?

  12. Catalyst Driver For PDL BioPharma Is ApproachingRead the original story w/Photo

    Tuesday Nov 15 | Seeking Alpha

    Patients with Alzheimer's Disease are in need of a disease altering therapy option rather than symptom management, as cost forecasts are shown to be on the rise. PDL BioPharma's know-how license to Lilly's solanezumab presents a catalyst for the stock with top line data by end of 2016.

    Comment?

  13. Calimmune Appoints As Executive Vice President And Chief Medical OfficerRead the original story

    Wednesday Nov 16 | BioSpace

    ... Dr. Yazji held senior clinical research physician and medical director roles at Exelixis, Inc., PDL BioPharma, Inc. and Johnson & Johnson. Dr. Yazji obtained his medical degree from the Pavlov School of Medicine, University of St. Petersburg, St. ...

    Comment?

  14. PDL Bio prices convertible debt offeringRead the original story w/Photo

    Thursday Nov 17 | Seeking Alpha

    PDL BioPharma prices its public offering of $150M of 2.75% Convertible Senior Notes due 2021. The conversion rate will initially be 262.2951 shares of common stock per $1,000 principal amount of the Notes .

    Comment?

  15. Biotech Stocks Under Scanner a " PDL BioPharma, Intrexon, 22nd Century, and Marinus PharmaRead the original story w/Photo

    Thursday Nov 17 | Freshnews

    ... likely boost M&A activities within the industry. Today, we have issued reports on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Intrexon Corp. (NYSE: XON), 22nd Century Group Inc. (NYSE MKT: XXII), and Marinus Pharmaceuticals Inc. ...

    Comment?

  16. Calimmune Appoints Salim Yazji, M.D. as Executive Vice President and Chief Medical OfficerRead the original story w/Photo

    Thursday Nov 17 | Freshnews

    ... Dr. Yazji held senior clinical research physician and medical director roles at Exelixis, Inc., PDL BioPharma, Inc. and Johnson & Johnson. Dr. Yazji obtained his medical degree from the Pavlov School of Medicine, University of St. Petersburg, St. ...

    Comment?

  17. PDL BioPharma Prices Public Offering Of $150.0 Million Of 2.75% Convertible Senior Notes Due 2021Read the original story

    Wednesday Nov 16 | BioSpace

    /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has agreed to sell $150.0 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 (the Notes) in an underwritten public offering. The ...

    Comment?

  18. Why H&R Block, PDL BioPharma, and Tutor Perini Slumped TodayRead the original story w/Photo

    Wednesday Nov 16 | Fox News

    ... reform through Congress, H&R Block could find that the coming tax season is its most favorable for a while. PDL BioPharma plunged 18% in the wake of the company's announcement Tuesday night that it would seek to offer $150 million in five-year ...

    Comment?

  19. Mid-Afternoon Market Update: StemCells Climbs On Asset Purchase Agreement; Endologix Shares DropRead the original story

    Wednesday Nov 16 | Benzinga

    ... to provide a two-year patient follow-up data from the EVAS-FORWARD IDE study of Nellix System. Shares of PDL BioPharma Inc (NASDAQ: PDLI ) were down 22 percent to $2.91 after the company reported a proposed $150 million public offering of new ...

    Comment?

  20. Mid-Day Market Update: Dow Falls 75 Points; Shipping Stocks Spike HigherRead the original story

    Wednesday Nov 16 | Benzinga

    ... to provide a two-year patient follow-up data from the EVAS-FORWARD IDE study of Nellix System. Shares of PDL BioPharma Inc (NASDAQ: PDLI ) were down 18 percent to $3.04 after the company reported a proposed $150 million public offering of new ...

    Comment?